ω-3或ω-6脂肪酸和皮质激素治疗活动性克罗恩病时胰岛素样生长因子及其结合蛋白的表达

作     者：Eivindson M. Grbak H. Nielsen J.N. 赵天智 

作者机构：Department of Medicine Vejle Hospital Kabbeltoft 25 DK-7100 Vejle Denmark Dr. 

出 版 物：《世界核心医学期刊文摘（胃肠病学分册）》 (Core Journals in Gastroenterology)

年 卷 期：2006年第2卷第5期

页      面：57-58页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：胰岛素样生长因子-Ⅰ 皮质激素治疗 脂肪酸 结合蛋白 生长激素(GH) 活动性 IGF-Ⅰ 病时 炎症性肠病 生长障碍 

摘      要：Objective. Catabolism and growth impairment are well-known complications of inflammatory bowel disease (IBD). This may be caused by the disease activity itself and/or the medical treatment, and both may lead to changes in the growth hormone (GH)/insulin-like growth factor I (IGF-I) axis. The aim of the present study was to examine the effects of enteral nutrition. Impact Powder(r), as adjuvant therapy to corticosteroid treatment on changes in the GH/IGF-I axis in patients with Crohn’ s disease (CD). Material and methods. The patients were randomized to 3-IP (ω -3-fatty acid (FA), 3 g/day) or 6-IP (ω -6-FA, 9 g/day). Changes in total IGF-I (tIGF-I) and total IGF-II (tIGF-II), free IGF-I (fIGF-I), IGF binding proteins (IGFBP-1 and IGFBP-3), IGFBP-3 protease activity and insulin levels were examined in 31 patients with active CD (CDAI: 186-603) during treatment with prednisolone (40 mg for 1 week) and tapering the dose by 5 mg/week. Clinical and biochemical markers of inflammation were studied at day 0, and after 5 and 9 weeks. Results. There were no differences at baseline between the two groups. During the treatment period, tIGFI, fIGF-I and IGFBP-3 increased significantly in both groups compared to baseline (p 0.05) without differences between the groups. Insulin and IGFBP-1 showed no significant changes throughout the treatment period. Conclusions. There was no difference between 3-IP and 6-IP as adjuvant enteral nutrition on the GH/IGF-I axis. The changes observed in the GH/IGFI axis are in line with previously published studies and may be explained by corticosteroid treatment; however, we cannot exclude an additional effect of ω 3-/ω 6 FA as adjuvant enteral nutrition.